Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of
ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.